Beckwith-Wiedemann syndrome (BWS) is a genetic syndrome associated with overgrowth and cancer predisposition, including predisposition to Wilms tumor (WT). Patients with BWS and BWS spectrum are screened from birth to age 7 years for BWS-associated cancers. However, in some cases a BWS-associated cancer may be the first recognized manifestation of the syndrome. We describe 12 patients diagnosed with BWS after presenting with a WT. We discuss the features of BWS in these patients and hypothesize that earlier detection of BWS by attention to its subtler manifestations could lead to earlier detection of children at risk for associated malignancies.
INTRODUCTION
Beckwith-Wiedemann syndrome (BWS, OMIM #130650) is a genetic overgrowth and cancer predisposition syndrome characterized by hemihypertrophy/lateralized overgrowth, macroglossia, macrosomia, organomegaly, hyperinsulinism, omphalocele/umbilical hernia, and distinct facial features. [1] [2] [3] The Beckwith-Wiedemann spectrum (BWSp) includes classic BWS and patients with molecular defects at 11p15, irrespective of the clinical presentation. 3 Patients with BWSp are at risk for embryonal tumors such as Wilms tumor (WT), hepatoblastoma, and neuroblastoma in the first 7 years of life. WT is the most common BWSp-associated cancer. 1, [4] [5] [6] [7] [8] Tumors develop in 5-10% of patients with BWSp, usually early in life, with variation in risk based on genomic subtype. [9] [10] [11] Recognizing the clinical manifestations of this genetic Abbreviations: BWS, Beckwith-Wiedemann syndrome; BWSp, Beckwith-Wiedemann syndrome spectrum; IC, Imprinting center; ILO, isolated lateralized overgrowth; pUPD11, paternal uniparental disomy 11; WT, Wilms tumor syndrome ensures that appropriate screening is initiated to allow for early tumor detection. The nature of this screening currently differs based on the definition of acceptable risk between the United States and Europe. 3, 8 In this case series, we describe a subset of patients who presented with WT and were subsequently diagnosed with BWSp.
BWSp is caused by genetic or epigenetic changes on chromosome 11p15, with either specific gene mutations or changes in DNA methylation in imprinting control (IC) regions 1 or 2, leading to a dysregulation in genes affecting growth. 1 The most common aberration found in 50% of BWSp cases is IC2 loss of methylation on the maternal chromosome. 1 Patients with BWSp can be monitored with serial abdominal imaging and serum alpha-fetoprotein levels to screen for BWSp-associated cancers such as WT, hepatoblastoma, and neuroblastoma; as more genotype-phenotype relationships are identified, it may be possible to tailor the monitoring plan based on the genetic subtype of BWSp. 9, 10 For example, the risk of WT is higher in patients with IC1 gain of methylation and pUPD11. 9, 10 Additionally, over half of patients with BWSp have a renal or genitourinary tract abnormality, including nephromegaly, cryptorchidism, nephrolithiasis, and dysplasia. 12 These renal abnormalities are associated with IC2 hypomethylation, IC1 hypermethylation, or pUPD11. 12 WT is associated with multiple WT1 mutations/aberrations, including Wilms-Aniridia-GU anomalies-Retardation (WAGR) syndrome and Denys-Drash syndrome. 13 In one large cohort study of patients with WT with or without indicators of an underlying genetic predisposition, 19% of patients had a germline predisposition to WT and 8% of those patients had a constitutional 11p15 aberration. 13 Additionally, there can be a range of tissue distribution of 11p15 alterations, as many of the patients with 11p15 aberrations in the kidney affected by WT exhibited constitutional mosacism. 14, 15 There are case reports of patients who were diagnosed with BWSp after presenting with WT. 16 However, there has yet to be a comprehensive evaluation of patients presenting with a BWSp-associated cancer who were subsequently diagnosed with BWSp.
METHODS
Our institutional database of patients with growth and epigenetic alterations (Children's Hospital of Philadelphia, IRB #13-010658) was reviewed for patients with WT, and further narrowed to those who were referred for BWSp evaluation after WT diagnosis. Testing included genome-wide SNP arrays (Illumina), methylation-sensitive PCR, and copy number analysis of the IC1 and IC2 loci, with reflex sequencing of CDKN1C when appropriate. 18, 19 Skin biopsies, when indicated, were obtained from the abdomen on the larger side of the body.
RESULTS
Of the 183 patients diagnosed with BWSp/isolated lateralized overgrowth (ILO) between January 2014 and July 2017, 12 were diagnosed after presenting with WT (Table 1 ). Age at diagnosis of WT ranged from 2 days to 9 years, stage at diagnosis ranged from 1 to 5, all patients had favorable histology, and three (25%) had multifocal or bilateral (synchronous or metachronous) tumors. All patients had some degree of ILO, not always with the same laterality as the affected kidney. Six of 12 patients had other findings of BWSp including infraorbital creases (n = 2), anterior ear creases (n = 2), large for gestational age at birth (n = 4), neonatal hypoglycemia (n = 1), and umbilical hernia (n = 1); the other six patients had isolated ILO without other findings. Eight of 12 patients met criteria for classical BWSp with or without molecular confirmation given ILO, WT diagnosis, plus additional features; the four that did not met criteria had ILO with unilateral WT, with incomplete molecular findings. All patients either had IC1 gain of methylation or pUPD11 in the WT-affected kidney (Table 2) . There were a variety of mosaic patterns, some with methylation changes in the affected kidney only (n = 7), others with methylation changes in bilateral kidneys (n = 4), and one with methylation changes in affected kidney as well as skin (n = 1).
DISCUSSION
WT is associated with several genetic predisposition syndromes, including BWSp, WAGR, Denys-Drash, Perlman, and other syndromes.
Patients with specific physical characteristics that are associated with these predispositions should undergo further genetic evaluation. 8, 13 This includes patients who present with multifocal or bilateral WT, who present at an early age, or who present with characteristic syndromic features such as aniridia, genitourinary abnormalities, or ILO.
The genetic evaluation should include testing for 11p15 epigenetic modifications and alterations associated with BWSp, which may necessitate testing multiple blood and tissue samples (including tumor, unaffected kidney, and/or skin biopsy from laterality affected by overgrowth). In our cohort, all affected patients had IC1 hypermethylation or pUPD11, which is consistent with previous studies, as these are the two most common genetic findings in BWSp patients with WT. 12 BWSp can affect patients in a mosaic pattern, as shown in this subset of patients. For this reason, multiple blood and tissue samples may be necessary to detect genetic changes associated with BWSp, and this requires some advance thinking in surgical planning.
The median age at WT presentation for our cohort was 26 months, which is below median age (42 months) for children with sporadic WT, but the age range for our patients with BWSp was broad (2 days to 109 months). Patients with a genetic predisposition to WT tend to be diagnosed earlier (median age 17 months). 17, 20 It is notable that 58% of patients in this cohort presented with stage 3-5 disease, which is similar to sporadic WT. 20, 21 Earlier recognition of conditions that predispose to WT is critical in order to initiate screening and early detection tumors, potentially sparing patients with the toxicity of anthracycline and radiation exposure. Further, the treatment approach to WT in children with a predisposition differs from that in children with sporadic WT, where upfront nephrectomy is often the standard of care. Because of the risk of developing metachronous tumors, children with BWSp and other WT predisposing syndromes are treated with neoadjuvant chemotherapy followed by nephron-sparing surgery (partial nephrectomy) to preserve renal tissue and function. 22 The specific mechanism of tumorigenesis in BWSp is unknown, although the genetic and epigenetic changes at 11p15.5 lead to higher expression of growth-promoting genes. 23 LGA at birth (>90%) Given that BWSp can present subtly and that ILO and other features may not be noted before WT diagnosis is made, a careful physical examination and testing for 11p cancer predisposing variants should be considered in any patient with newly-diagnosed WT.
